New shot could replace IV drips for rare muscle disease
NCT ID NCT05514873
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This study tested whether people with generalized myasthenia gravis could safely switch from intravenous (IV) infusions of complement inhibitors to daily injections of zilucoplan. Twenty-six participants who were stable on IV therapy switched to the subcutaneous shot. The main focus was on safety and tolerability, with secondary measures of symptom control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zilucoplan
What this could lead to
If successful, this could offer a more convenient at-home injection option for people with generalized myasthenia gravis who currently need regular IV infusions.
What could go wrong
This is a small, single-arm study (26 people) with no comparison group, so results may not apply broadly. The main goal is safety, not proof of superior effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mg0017 50076
Columbus, Ohio, 43221, United States
-
Mg0017 50086
Charlotte, North Carolina, 28207, United States
-
Mg0017 50099
San Francisco, California, 94143, United States
-
Mg0017 50111
Seattle, Washington, 98195-0001, United States
-
Mg0017 50304
Dallas, Texas, 75390-8866, United States
-
Mg0017 50555
Austin, Texas, 78759, United States
-
Mg0017 50556
Chapel Hill, North Carolina, 27599, United States
-
Mg0017 50557
O'Fallon, Illinois, 62269, United States
-
Mg0017 50559
Los Angeles, California, 90095, United States
-
Mg0017 50564
Scottsdale, Arizona, 85251, United States
-
Mg0017 50569
Greenfield, Wisconsin, 53228, United States
-
Mg0017 50593
Rancho Mirage, California, 92270, United States